Dyadic International Inc. (DYAI) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Company: Dyadic International, Inc.
Reporting Period: Quarter and six months ended June 30, 2024.
Business Model: Global biotechnology company utilizing proprietary microbial protein production platforms (C1-cell and Dapibus™) for pharmaceutical, animal health, and non-pharmaceutical applications (food, nutrition). Revenue is derived primarily from research collaborations, licensing agreements, and government grants. The company has no approved products for commercial sale.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $385,896 | $837,159 | $720,513 | $1,815,211 |
| Net Loss | $(2,045,223) | $(2,152,960) | $(4,054,819) | $(3,109,404) |
| Loss Per Share (Basic/Diluted) | $(0.07) | $(0.07) | $(0.14) | $(0.11) |
| Cash & Equivalents (End of Period) | $6,133,398 (June 30, 2024) Short-term investments: $3,964,517 |
|||
| Total Assets | ||||
| Total Liabilities | $7,462,190 (June 30, 2024) | |||
| Convertible Notes Outstanding | ~$5.6M Principal ($4.0M Third Party, $1.6M Related Party) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 54% in Q2 2024 compared to Q2 2023, and 60% on a YTD basis. This is primarily due to the winding down of large research collaborations (specifically with Janssen, which ended in Dec 2023) and the absence of license revenue recognized in the current period.
- Expense Reduction: Research and Development (R&D) expenses decreased significantly (44% in Q2, 40% YTD) due to the completion of the DYAI-100 COVID-19 vaccine Phase 1 clinical trial and reduced internal project activity.
- Operating Loss Improvement: Despite lower revenue, the operating loss narrowed slightly in Q2 ($2.04M vs $2.29M) due to the sharper decline in R&D costs. However, General and Administrative (G&A) expenses increased 14.6% in Q2 and 17.8% YTD, driven by higher legal fees, business development costs, and share-based compensation.
- Debt Financing: In March 2024, the company issued $6.0 million in 8% Senior Secured Convertible Promissory Notes. This introduced new interest expenses ($88,634 in Q2) which were not present in the prior year period.
- Investment Activity: The company significantly increased its short-term investment securities portfolio from $0.75M (Dec 2023) to $3.96M (June 2024), utilizing proceeds from the convertible note offering.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects existing cash, investments, and proceeds from the convertible notes to be sufficient to meet operational requirements for at least the next 12 months. However, future capital raises may be necessary and could be dilutive.
- Recent Developments:
- Proliant Agreement: Entered a new agreement in June 2024 for recombinant serum albumin; received an initial $500,000 payment in July 2024 (subsequent to period end).
- Product Progress: Completed development of DNASE-1; ongoing sampling for recombinant transferrin and bovine albumin for the alternative protein industry.
- Vaccine Candidates: Pre-clinical data presented for H5N1 "Bird Flu" vaccine candidates for both human and animal health applications.
- Risks:
- History of Losses: The company has a history of net losses and negative operating cash flows.
- Customer Concentration: Significant reliance on a few customers; for the six months ended June 2024, five customers accounted for 70.3% of R&D revenue.
- Regulatory & Development Risk: Success depends on regulatory approval of products and successful clinical trials, which are uncertain.
- Debt Covenants: The new convertible notes are secured by substantially all company assets and carry an 8% interest rate.
Key Facts for Investor Verification
- Cash Runway: Verify if the $10.1M in total liquid assets (cash + short-term investments) is sufficient to cover the ~$4M annualized burn rate given the recent increase in G&A expenses.
- Revenue Sustainability: Assess the pipeline of new collaborations to replace the revenue lost from the Janssen and other winding-down contracts.
- Debt Conversion: Monitor the conversion price of the new notes ($1.79/share) relative to the current market price to gauge potential dilution.
- Related Party Transactions: Note that $2.0M of the new convertible notes were purchased by related parties (family members/trusts of the CEO).
- Subsequent Events: Confirm the receipt and accounting treatment of the $500,000 upfront payment from the Proliant agreement received in July 2024.